Lenoss Medical’s OsteoPearl procedure reached its 150th case, according to a March 27 news release shared with Becker’s. More than half of the 150 cases were completed since September. OsteoPearl is an allograft designed to augment vertebral compression fractures. It…
Biologics
From new partnerships to product launches, here are 12 key developments in orthobiologics during the first quarter of 2025. 1. Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology. Under the agreement…
Miach Orthopaedics' BEAR (bridge-enhanced ACL restoration) implant is now available to treat children and adolescents with anterior cruciate ligament tears after the FDA expanded its clearance.
Atreon Orthopedics earned expanded FDA 510(k) clearance for its Rotium bioreabsorbable wick, according to a March 6 news release.
Spine biologics is gaining more interest, and its innovation will be rooted in tailored patient care, Craig McMains, MD, said.
Advertisement
Atreon Orthopedics earned FDA 510(k) clearance for the BioCharge autobiologic matrix and launched the new product, according to a Feb. 20 news release.
From new study findings to product launches, here are eight headlines to know in the orthobiologics space since Jan. 13:
Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.
The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from ResearchandMarkets.com.
Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.